Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

10 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
An HLA-A*11:01-Binding Neoantigen from Mutated NPM1 as Target for TCR Gene Therapy in AML.
van der Lee DI, Koutsoumpli G, Reijmers RM, Honders MW, de Jong RCM, Remst DFG, Wachsmann TLA, Hagedoorn RS, Franken KLMC, Kester MGD, Harber KJ, Roelofsen LM, Schouten AM, Mulder A, Drijfhout JW, Veelken H, van Veelen PA, Heemskerk MHM, Falkenburg JHF, Griffioen M. van der Lee DI, et al. Among authors: wachsmann tla. Cancers (Basel). 2021 Oct 27;13(21):5390. doi: 10.3390/cancers13215390. Cancers (Basel). 2021. PMID: 34771556 Free PMC article.
A library of cancer testis specific T cell receptors for T cell receptor gene therapy.
de Rooij MAJ, Remst DFG, van der Steen DM, Wouters AK, Hagedoorn RS, Kester MGD, Meeuwsen MH, Wachsmann TLA, de Ru AH, van Veelen PA, Verdegaal EME, Falkenburg JHF, Heemskerk MHM. de Rooij MAJ, et al. Among authors: wachsmann tla. Mol Ther Oncolytics. 2022 Dec 2;28:1-14. doi: 10.1016/j.omto.2022.11.007. eCollection 2023 Mar 16. Mol Ther Oncolytics. 2022. PMID: 36589698 Free PMC article.
Broadly applicable TCR-based therapy for multiple myeloma targeting the immunoglobulin J chain.
Meeuwsen MH, Wouters AK, Wachsmann TLA, Hagedoorn RS, Kester MGD, Remst DFG, van der Steen DM, de Ru AH, van Hees EP, Kremer M, Griffioen M, van Veelen PA, Falkenburg JHF, Heemskerk MHM. Meeuwsen MH, et al. Among authors: wachsmann tla. J Hematol Oncol. 2023 Feb 27;16(1):16. doi: 10.1186/s13045-023-01408-6. J Hematol Oncol. 2023. PMID: 36850001 Free PMC article.
PRAME and CTCFL-reactive TCRs for the treatment of ovarian cancer.
van Amerongen RA, Tuit S, Wouters AK, van de Meent M, Siekman SL, Meeuwsen MH, Wachsmann TLA, Remst DFG, Hagedoorn RS, van der Steen DM, de Ru AH, Verdegaal EME, van Veelen PA, Falkenburg JHF, Heemskerk MHM. van Amerongen RA, et al. Among authors: wachsmann tla. Front Immunol. 2023 Mar 21;14:1121973. doi: 10.3389/fimmu.2023.1121973. eCollection 2023. Front Immunol. 2023. PMID: 37026005 Free PMC article.
High-affinity CD8 variants enhance the sensitivity of pMHCI antigen recognition via low-affinity TCRs.
Knezevic L, Wachsmann TLA, Francis O, Dockree T, Bridgeman JS, Wouters A, de Wet B, Cole DK, Clement M, McLaren JE, Gostick E, Ladell K, Llewellyn-Lacey S, Price DA, van den Berg HA, Tabi Z, Sessions RB, Heemskerk MHM, Wooldridge L. Knezevic L, et al. Among authors: wachsmann tla. J Biol Chem. 2023 Aug;299(8):104981. doi: 10.1016/j.jbc.2023.104981. Epub 2023 Jun 28. J Biol Chem. 2023. PMID: 37390984 Free PMC article.
CD3 aptamers promote expansion and persistence of tumor-reactive T cells for adoptive T cell therapy in cancer.
Menon AP, Villanueva H, Meraviglia-Crivelli D, van Santen HM, Hellmeier J, Zheleva A, Nonateli F, Peters T, Wachsmann TLA, Hernandez-Rueda M, Huppa JB, Schütz GJ, Sevcsik E, Moreno B, Pastor F. Menon AP, et al. Among authors: wachsmann tla. Mol Ther Nucleic Acids. 2024 Apr 23;35(2):102198. doi: 10.1016/j.omtn.2024.102198. eCollection 2024 Jun 11. Mol Ther Nucleic Acids. 2024. PMID: 38745854 Free PMC article.
Erratum: A library of cancer testis specific T cell receptors for T cell receptor gene therapy.
de Rooij MAJ, Remst DFG, van der Steen DM, Wouters AK, Hagedoorn RS, Kester MGD, Meeuwsen MH, Wachsmann TLA, de Ru AH, van Veelen PA, Verdegaal EME, Falkenburg JHF, Heemskerk MHM. de Rooij MAJ, et al. Among authors: wachsmann tla. Mol Ther Oncolytics. 2023 Oct 23;31:100738. doi: 10.1016/j.omto.2023.100738. eCollection 2023 Dec 19. Mol Ther Oncolytics. 2023. PMID: 37920174 Free PMC article.